A retrospective study of cabazitaxel and abiraterone acetate in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel: CAST

Trial Profile

A retrospective study of cabazitaxel and abiraterone acetate in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel: CAST

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs Cabazitaxel (Primary) ; Abiraterone acetate
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2015 New trial record
    • 15 Mar 2015 Primary endpoint (Overall survival), has been not met, as per an article published in the International Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top